Algert Global’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-255,131
| Closed | -$2.22M | – | 414 |
|
|
2018
Q2 | $2.22M | Sell |
255,131
-11,062
| -4% | -$100K | 0.46% | 81 |
|
|
2018
Q1 | $2.7M | Buy |
266,193
+46,454
| +21% | +$390K | 0.52% | 65 |
|
|
2017
Q4 | $1.07M | Buy |
219,739
+75,174
| +52% | +$366K | 0.25% | 161 |
|
|
2017
Q3 | $658K | Buy |
144,565
+24,530
| +20% | +$115K | 0.15% | 204 |
|
|
2017
Q2 | $606K | Buy |
120,035
+11,720
| +11% | +$52.4K | 0.17% | 198 |
|
|
2017
Q1 | $514K | Buy |
108,315
+24,270
| +29% | +$123K | 0.14% | 228 |
|
|
2016
Q4 | $471K | Buy |
84,045
+4,300
| +5% | +$23.6K | 0.13% | 238 |
|
|
2016
Q3 | $443K | Sell |
79,745
-10,780
| -12% | -$71.3K | 0.13% | 255 |
|
|
2016
Q2 | $635K | Hold |
90,525
| – | – | 0.26% | 156 |
|
|
2016
Q1 | $598K | Buy |
90,525
+53,508
| +145% | +$394K | 0.22% | 173 |
|
|
2015
Q4 | $381K | Buy |
+37,017
| New | +$429K | 0.18% | 212 |
|
|
2014
Q1 | – | Sell |
-59,063
| Closed | -$390K | – | 397 |
|
|
2013
Q4 | $390K | Buy |
59,063
+29,729
| +101% | +$202K | 0.1% | 255 |
|
|
2013
Q3 | $213K | Buy |
+29,334
| New | +$197K | 0.06% | 306 |
|
Algert Global's JNP Position: Q3 2018 in Review
Algert Global sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 255,131 shares — an estimated $2.22M sold.
Algert Global first reported a position in JNP in Q3 2013 and held it in 13 quarters. The position peaked at $2.7M in Q1 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Algert Global reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Algert Global sold 255,131 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $2.22M.
- Algert Global first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 13 quarters.
- Algert Global's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $2.7M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Algert Global's 13F filing for Q3 2018, filed 14 Nov 2018.